Mack Randall 4
4 · Recro Pharma, Inc. · Filed Jan 22, 2018
Insider Transaction Report
Form 4
Mack Randall
Senior VP, Development
Transactions
- Exercise/Conversion
Common Stock
2018-01-18+3,100→ 34,713 total - Tax Payment
Common Stock
2018-01-18$8.89/sh−961$8,543→ 33,752 total - Exercise/Conversion
Restricted Stock Units
2018-01-18−3,100→ 9,300 total→ Common Stock (3,100 underlying)
Footnotes (2)
- [F1]Restricted stock units convert into common stock on a one-for-one basis.
- [F2]On January 18, 2017, the reporting person was granted 12,400 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date.